 Connection
Paul Bunn to Erlotinib Hydrochloride
This is a "connection" page, showing publications Paul Bunn has written about Erlotinib Hydrochloride.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.003 |
|
|
|
-
Hirsch FR, Bunn PA. Adjuvant TKIs in NSCLC: what can we learn from RADIANT? Nat Rev Clin Oncol. 2015 Dec; 12(12):689-90.
Score: 0.508
-
Hirsch FR, Varella-Garcia M, Dziadziuszko R, Xiao Y, Gajapathy S, Skokan M, Lin M, O'Neill V, Bunn PA. Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer. Clin Cancer Res. 2008 Oct 01; 14(19):6317-23.
Score: 0.078
-
Bunn PA. Can acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors be overcome by different small-molecule tyrosine kinase inhibitors? J Clin Oncol. 2007 Jun 20; 25(18):2504-5.
Score: 0.071
-
Bunn PA. Can a single pill replace doublet chemotherapy in first-line therapy of advanced non-small cell lung cancer? Clin Cancer Res. 2006 Oct 15; 12(20 Pt 1):5919-20.
Score: 0.068
-
Hirsch FR, Bunn PA. Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations? J Clin Oncol. 2005 Dec 20; 23(36):9044-7.
Score: 0.064
-
Herbst RS, Bunn PA. Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5813-24.
Score: 0.056
-
Iyengar P, Kavanagh BD, Wardak Z, Smith I, Ahn C, Gerber DE, Dowell J, Hughes R, Abdulrahman R, Camidge DR, Gaspar LE, Doebele RC, Bunn PA, Choy H, Timmerman R. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol. 2014 Dec 01; 32(34):3824-30.
Score: 0.030
-
Hirsch FR, Bunn PA, Herbst RS. "Companion diagnostics": has their time come and gone? Clin Cancer Res. 2014 Sep 01; 20(17):4422-4.
Score: 0.029
-
Shepherd FA, Bunn PA, Paz-Ares L. Lung cancer in 2013: state of the art therapy for metastatic disease. Am Soc Clin Oncol Educ Book. 2013; 339-46.
Score: 0.026
-
Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA, Aisner DL, Gaspar LE, Kavanagh BD, Doebele RC, Camidge DR. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012 Dec; 7(12):1807-1814.
Score: 0.026
-
Witta SE, Jotte RM, Konduri K, Neubauer MA, Spira AI, Ruxer RL, Varella-Garcia M, Bunn PA, Hirsch FR. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol. 2012 Jun 20; 30(18):2248-55.
Score: 0.025
-
Hirsch FR, Kabbinavar F, Eisen T, Martins R, Schnell FM, Dziadziuszko R, Richardson K, Richardson F, Wacker B, Sternberg DW, Rusk J, Franklin WA, Varella-Garcia M, Bunn PA, Camidge R, Camidge DR. A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer. J Clin Oncol. 2011 Sep 10; 29(26):3567-73.
Score: 0.024
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|